Stock Events

Stock Events

TNF Pharmaceuticals 

$0.5518
72
+$0.02+4.09%Thursday 19:59

Statistics

Day High
0.5899
Day Low
0.5347
52W High
5.2
52W Low
0.5301
Volume
837,905
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Jan 1Expected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-27.16MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences is a biopharmaceutical company that competes with MyMD in the development of treatments for viral diseases, inflammatory and fibrotic diseases, which overlaps with MyMD's focus on immune-mediated diseases.
Abbvie
ABBV
Mkt Cap464.43B
AbbVie competes in the immunology and oncology sectors, directly challenging MyMD's efforts in developing therapies for immune system diseases and cancer.
AMGEN
AMGN
Mkt Cap217.9B
Amgen is a biotech firm focusing on novel therapies in areas like inflammation, which competes with MyMD's research into immune system modulation.
Bristol-Myers Squibb
BMY
Mkt Cap124.91B
Bristol Myers Squibb operates in the biopharmaceutical field, focusing on cancer and immune system disorders, directly competing with MyMD's therapeutic areas.
Merck
MRK
Mkt Cap356.01B
Merck is known for its work in pharmaceuticals and vaccines, including treatments for immune system disorders, making it a competitor to MyMD.
Pfizer
PFE
Mkt Cap158.45B
Pfizer develops and manufactures drugs and vaccines, including for autoimmune diseases, competing with MyMD's focus on immune system modulation.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, including immune-mediated diseases, directly competing with MyMD's focus areas.
Novartis
NVS
Mkt Cap268B
Novartis focuses on a broad range of healthcare areas, including advanced therapies in immunology and oncology, competing with MyMD.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurology and rare diseases but also competes in the broader biopharmaceutical market against companies like MyMD.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals concentrates on treating the underlying causes of diseases in areas like cystic fibrosis, which involves modulation of the immune system, indirectly competing with MyMD.

About

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Show More
CEO
Mr. Ian Rhodes CPA
Employees
2
Country
United States
ISIN
US62856X2018

Listings

XNAS
US
QCLS
MU
DE
DQS.MU
LSE
GB
0A8D.LSE
BOATS
BOATS
QCLS.BOATS

0 Comments

Share your thoughts

FAQs

What is TNF Pharmaceuticals stock price today?▼
The current price of TNFA is $0.55 USD — it has increased by +4.09% in the past 24 hours. Watch TNF Pharmaceuticals stock price performance more closely on the chart.
What is TNF Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange TNF Pharmaceuticals stocks are traded under the ticker TNFA.
What is TNF Pharmaceuticals revenue for the last year?▼
TNF Pharmaceuticals revenue for the last year amounts to 0 USD.
What is TNF Pharmaceuticals net income for the last year?▼
TNFA net income for the last year is -27.16M USD.
How many employees does TNF Pharmaceuticals have?▼
As of October 16, 2026, the company has 2 employees.
In which sector is TNF Pharmaceuticals located?▼
TNF Pharmaceuticals operates in the Health & Wellness sector.
When did TNF Pharmaceuticals complete a stock split?▼
The last stock split for TNF Pharmaceuticals was on September 2, 2025 with a ratio of 1:100.
Where is TNF Pharmaceuticals headquartered?▼
TNF Pharmaceuticals is headquartered in New York, United States.